We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
-7.45%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$549M
AUM Growth
-$91.5M
Cap. Flow
+$1.02M
Cap. Flow %
0.19%
Top 10 Hldgs %
42.34%
Holding
105
New
18
Increased
27
Reduced
20
Closed
23

Top Buys

Rank Stock Value
1
TSEM icon
Tower Semiconductor
TSEM
+$9.69M
2
CYTK icon
Cytokinetics
CYTK
+$7.79M
3
AMD icon
Advanced Micro Devices
AMD
+$5.25M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.87M
5
PMN icon
ProMIS Neurosciences
PMN
+$4.77M

Top Sells

Rank Stock Value
1
NICE icon
Nice
NICE
+$9.95M
2
NVMI
Nova
NVMI
+$8.21M
3
CAMT icon
Camtek
CAMT
+$6.75M
4
SAGE
Sage Therapeutics
SAGE
+$6.02M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.29M

Sector Composition

Rank Sector Weight
1 Healthcare 60.67%
2 Miscellaneous 27.99%
3 Technology 7.83%
4 Consumer Discretionary 2.21%
5 Communication Services 0.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAWN
26
DELISTED
Day One Biopharmaceuticals
DAWN
$6.5M 1.18%
530,000
– –
KURA icon
27
Kura Oncology
KURA
$1.04B
$6.41M 1.17%
703,287
+100,000
+17% +$1.02M
ALNY icon
28
Alnylam Pharmaceuticals
ALNY
$32.9B
$6.39M 1.16%
36,101
-3,899
-10% -$744K
NICE icon
29
Nice
NICE
$6.17B
$6.37M 1.16%
37,482
-50,000
-57% -$9.95M
PNT
30
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$6.35M 1.16%
952,642
– –
TEVA icon
31
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
$6.12M 1.11%
600,000
-450,000
-43% -$4.19M
NVS icon
32
Novartis
NVS
$268B
$6.11M 1.11%
60,000
– –
SRPT icon
33
Sarepta Therapeutics
SRPT
$2.18B
$6.06M 1.1%
50,000
– –
MRUS
34
DELISTED
Merus
MRUS
$5.97M 1.09%
253,333
-25,000
-9% -$606K
IRON icon
35
Disc Medicine
IRON
$2.66B
$5.23M 0.95%
111,398
-59,180
-35% -$2.96M
INZY
36
DELISTED
Inozyme Pharma
INZY
$5.19M 0.94%
1,234,907
+102,940
+9% +$524K
AMD icon
37
Advanced Micro Devices
AMD
$890B
$4.97M 0.91%
+48,320
New +$5.25M
CLDX icon
38
Celldex Therapeutics
CLDX
$3.06B
$4.95M 0.9%
180,000
+20,000
+13% +$627K
ETNB
39
DELISTED
89bio
ETNB
$4.93M 0.9%
319,301
+184,301
+137% +$3.09M
PTCT icon
40
PTC Therapeutics
PTCT
$5.68B
$4.9M 0.89%
218,459
+118,359
+118% +$4.4M
INBX
41
DELISTED
Inhibrx, Inc. Common Stock
INBX
$4.7M 0.86%
256,371
+206,371
+413% +$4.32M
META icon
42
Meta Platforms (Facebook)
META
$1.74T
$4.57M 0.83%
+15,220
New +$4.59M
GRCL
43
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$4.41M 0.8%
1,531,497
+302,832
+25% +$1.11M
ATXS
44
DELISTED
Astria Therapeutics
ATXS
$4.33M 0.79%
580,599
+109,581
+23% +$934K
MLYS icon
45
Mineralys Therapeutics
MLYS
$2.47B
$4.33M 0.79%
455,400
+50,000
+12% +$652K
RCKT icon
46
Rocket Pharmaceuticals
RCKT
$384M
$4.28M 0.78%
209,040
-26,960
-11% -$490K
COGT icon
47
Cogent Biosciences
COGT
$5.76B
$4.09M 0.75%
420,000
– –
JSPR icon
48
Jasper Therapeutics
JSPR
$21.1M
$3.98M 0.73%
568,713
+141,312
+33% +$1.72M
PMN icon
49
ProMIS Neurosciences
PMN
$121M
$3.69M 0.67%
+73,362
New +$4.77M
XBI icon
50
State Street SPDR S&P Biotech ETF
XBI
$10.7B
$3.65M 0.67%
50,000
– –
1
2
3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q3 2023 Portfolio in Review

As of Q3 2023, Sphera Funds Management held 105 positions worth $549M, down 14% from $640M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management's Q3 2023 filing shows 18 new, 27 increased, 20 reduced and 23 closed positions. Its largest new stake was Cytokinetics: 233,933 shares worth $6.89M. The largest sale was Nice, an estimated $9.95M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q3 2023 buy was Cytokinetics: 233,933 shares worth $6.89M.
  • Sphera Funds Management added most to Tower Semiconductor in Q3 2023, an estimated $9.69M increase.
  • Sphera Funds Management's biggest Q3 2023 reduction was Nice, cutting an estimated $9.95M.
  • Sphera Funds Management fully exited Nova in Q3 2023, selling an estimated $8.21M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $549M portfolio in Q3 2023.
  • Sphera Funds Management opened 18 new positions and closed 23 in Q3 2023.
  • Sphera Funds Management's portfolio value fell 14% quarter-over-quarter to $549M.

Based on Sphera Funds Management's 13F filing for Q3 2023, filed 14 Nov 2023.